Tumor Molecular Profiling and Stratification
Tumor molecular profiling and stratification is the branch of molecular pathology that characterizes a cancer by its genetic and molecular alterations and uses that information to classify tumors into biologically and clinically meaningful subgroups. Rather than relying on tissue of origin and morphology alone, it reads the genome, transcriptome, and other molecular layers of a tumor to define what is driving it and how it differs from other cancers that look similar under the microscope.
Definition
Tumor molecular profiling is the systematic detection of somatic alterations - mutations, copy-number changes, structural rearrangements, and other molecular features - in tumor tissue or circulating tumor material; molecular stratification is the use of these profiles to assign tumors to subgroups with shared biology, prognosis, or predicted response.
Scope
This area orients the reader to the molecular characterization of tumors: genomic profiling and multigene panels, the driver mutations and hotspots that initiate and sustain cancers, fusion genes arising from chromosomal rearrangements, predictive biomarkers that flag therapeutic targets, and genome-wide signatures such as tumor mutational burden and microsatellite instability. It is a reference overview of concepts and evidence in molecular oncologic pathology, not a protocol for testing or treating any individual patient.
Sub-topics
Core questions
- What somatic alterations define a given tumor, and which of them are likely driving its growth?
- How can tumors that look alike histologically be separated into distinct molecular subgroups?
- Which molecular features predict response or resistance to a specific therapy?
- How are sequence variants interpreted and reported so that findings are reproducible across laboratories?
Key concepts
- Somatic versus germline alterations
- Driver versus passenger mutations
- Multigene sequencing panels
- Comprehensive genomic profiling
- Oncogenic signaling pathways
- Predictive versus prognostic biomarkers
- Variant interpretation and tiered reporting
- Molecular subtyping and stratification
Mechanisms
Cancers accumulate somatic alterations across the genome, and only a subset of these - the drivers - confer the selective growth advantage that defines a tumor. Profiling technologies, especially massively parallel (next-generation) sequencing, detect point mutations, insertions and deletions, copy-number changes, and structural rearrangements across many genes simultaneously, and increasingly across whole exomes or genomes. Analysis of large cohorts such as The Cancer Genome Atlas has shown that these alterations converge on a limited set of oncogenic signaling pathways, which provides the conceptual basis for grouping diverse tumors by shared biology rather than by site of origin alone. Detected variants are then interpreted against curated evidence and reported in tiers that reflect their clinical and biological significance.
Clinical relevance
Molecular profiling underlies the modern practice of describing cancers in molecular terms and underpins much of precision oncology, where subgroups defined by specific alterations are studied in relation to targeted therapies. As a reference area it explains how molecular evidence about tumors is generated, validated, and classified; it characterizes biology and the structure of evidence and is not itself a source of diagnostic or treatment recommendations for individuals.
Epidemiology
Comprehensive sequencing of large tumor series has mapped the prevalence of driver alterations across cancer types, showing that most adult solid tumors carry a small number of driver events against a larger background of passenger mutations, and that the same pathways recur across many tumor types at differing frequencies. These cohort analyses provide the population-level picture against which an individual tumor's profile is interpreted.
History
Tumor characterization moved from morphology and immunohistochemistry toward molecular definition over the late twentieth and early twenty-first centuries, as the identification of individual oncogenes and tumor-suppressor genes gave way to genome-scale studies. The advent of massively parallel sequencing made it feasible to profile many genes at once in routine specimens, and large consortium efforts catalogued the recurrent alterations and pathways of human cancer. Professional bodies subsequently issued standards for interpreting and reporting somatic variants, consolidating molecular profiling as a defined area of diagnostic pathology.
Key figures
- Bert Vogelstein
- Kenneth Kinzler
- Victor Velculescu
Related topics
Seminal works
- vogelstein-2013
- sanchezvega-2018
- frampton-2013
Frequently asked questions
- How does molecular stratification differ from traditional tumor classification?
- Traditional classification groups tumors mainly by tissue of origin and microscopic appearance, whereas molecular stratification groups them by the genetic and molecular alterations they carry, so that tumors looking alike under the microscope may fall into different molecular subgroups, and tumors from different organs may share one.
- What is the difference between a driver and a passenger mutation?
- A driver mutation confers a selective growth advantage and contributes to the development of the cancer, while a passenger mutation is acquired along the way but does not itself promote tumor growth; distinguishing the two is a central goal of molecular profiling.